Proteoglycan expression in bleomycin lung fibroblasts: role of transforming growth factor-beta(1) and interferon-gamma.
Bleomycin (BM)-induced pulmonary fibrosis involves excess production of proteoglycans (PGs). Because transforming growth factor-beta(1) (TGF-beta(1)) promotes fibrosis, and interferon-gamma (IFN-gamma) inhibits it, we hypothesized that TGF-beta(1) treatment would upregulate PG production in fibrotic lung fibroblasts, and IFN-gamma would abrogate this effect. Primary lung fibroblast cultures were established from rats 14 days after intratracheal instillation of saline (control) or BM (1.5 units). PGs were extracted and subjected to Western blot analysis. Bleomycin-exposed lung fibroblasts (BLF) exhibited increased production of versican (VS), heparan sulfate proteoglycan (HSPG), and biglycan (BG) compared with normal lung fibroblasts (NLF). Compared with NLF, BLF released significantly increased amounts of TGF-beta(1). TGF-beta(1) (5 ng/ml for 48 h) upregulated PG expression in both BLF and NLF. Incubation of BLF with anti-TGF-beta antibody (1, 5, and 10 microg/ml) inhibited PG expression in a dose-dependent manner. Treatment of BLF with IFN-gamma (500 U. ml(-1) x 48 h) reduced VS, HSPG, and BG expression. Furthermore, IFN-gamma inhibited TGF-beta(1)-induced increases in PG expression by these fibroblasts. Activation of fibroblasts by TGF-beta(1) promotes abnormal deposition of PGs in fibrotic lungs; downregulation of TGF-beta(1) by IFN-gamma may have potential therapeutic benefits in this disease.
Venkatesan
Narayanan
N
Meakins-Christie Laboratories, Royal Victoria Hospital, Montreal, Quebec, Canada H2X 2P2.
Roughley
Peter J
PJ
Ludwig
Mara S
MS
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D058578:Biglycan; D001761:Bleomycin / Q000494:pharmacology; D002455:Cell Division / Q000502:physiology; D002470:Cell Survival / Q000502:physiology; D002478:Cells, Cultured; D011508:Chondroitin Sulfate Proteoglycans / Q000032:analysis / Q000096:biosynthesis; D016326:Extracellular Matrix Proteins; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D019812:Heparan Sulfate Proteoglycans / Q000032:analysis / Q000096:biosynthesis*; D066298:In Vitro Techniques; D007371:Interferon-gamma / Q000502:physiology*; D037181:Lectins, C-Type; D008297:Male; D011509:Proteoglycans / Q000032:analysis / Q000096:biosynthesis; D011658:Pulmonary Fibrosis / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000378:metabolism* / Q000494:pharmacology; D053773:Transforming Growth Factor beta1; D015854:Up-Regulation / Q000502:physiology; D053675:Versicans
D000906:Antibodies; D000964:Antimetabolites, Antineoplastic; C546886:Bgn protein, rat; D058578:Biglycan; D011508:Chondroitin Sulfate Proteoglycans; D016326:Extracellular Matrix Proteins; D019812:Heparan Sulfate Proteoglycans; D037181:Lectins, C-Type; D011509:Proteoglycans; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; C508324:Vcan protein, rat; D001761:Bleomycin; D053675:Versicans; D007371:Interferon-gamma